Department of Emergency Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA.
Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA.
Acad Emerg Med. 2022 Jan;29(1):28-40. doi: 10.1111/acem.14369. Epub 2021 Sep 7.
Despite evidence demonstrating the safety and efficacy of buprenorphine for the treatment of emergency department (ED) patients with opioid use disorder (OUD), incorporation into clinical practice has been highly variable. We explored barriers and facilitators to the prescription of buprenorphine, as perceived by practicing ED clinicians.
We conducted semistructured interviews with a purposeful sample of ED clinicians. An interview guide was developed using the Consolidated Framework for Implementation Research and Theoretical Domains Framework implementation science frameworks. Interviews were recorded, transcribed, and analyzed in an iterative process. Emergent themes were identified, discussed, and organized.
We interviewed 25 ED clinicians from 11 states in the United States. Participants were diverse with regard to years in practice and practice setting. While outer setting barriers such as the logistic costs of getting a DEA-X waiver and lack of clear follow-up for patients were noted by many participants, individual-level determinants driven by emotion (stigma), beliefs about consequences and roles, and knowledge predominated. Participants' responses suggested that implementation strategies should address stigma, local culture, knowledge gaps, and logistic challenges, but that a particular order to addressing barriers may be necessary.
While some participants were hesitant to adopt a "new" role in treating patients with medications for OUD, many already had and gave concrete strategies regarding how to encourage others to embrace their attitude of "this is part of emergency medicine now."
尽管有证据表明丁丙诺啡用于治疗急诊科(ED)阿片类药物使用障碍(OUD)患者是安全有效的,但将其纳入临床实践的情况差异很大。我们探讨了 ED 临床医生认为丁丙诺啡处方的障碍和促进因素。
我们对 ED 临床医生进行了有针对性的半结构式访谈。使用综合实施研究框架和理论领域框架实施科学框架制定了访谈指南。以迭代的方式记录、转录和分析访谈。确定、讨论和组织了出现的主题。
我们采访了来自美国 11 个州的 25 名 ED 临床医生。参与者在实践年限和实践环境方面存在差异。尽管许多参与者提到了外在环境障碍,如获得 DEA-X 豁免的物流成本和患者缺乏明确的后续治疗,但主要的是由情绪(耻辱感)、对后果和角色的信念以及知识驱动的个体水平决定因素。参与者的反应表明,实施策略应该解决耻辱感、当地文化、知识差距和物流挑战,但可能需要按特定顺序解决障碍。
虽然一些参与者对在治疗阿片类药物使用障碍患者时采用“新”角色犹豫不决,但许多参与者已经有了具体的策略,并且愿意鼓励其他人接受“现在这是急诊医学的一部分”的态度。